Strong second quarter for Synthes despite effects of downturn
This article was originally published in Clinica
Executive Summary
Orthopaedic specialist Synthes reported a strong second quarter. This was despite ongoing negative economic conditions and pricing pressures in North America and Europe, as well as government-sanctioned price reductions in Japan. The Solothurn, Switzerland-based company recorded sales of around $892.2m for the period, a 7% improvement on the same quarter last year. Second-quarter revenue was up in North America (+4% to $531.4m), Europe (+3% to $195.3m), Asia-Pacific (+22% to $101.6m) and the rest of the world (+39% to $63.9m). In Q1, the firm displayed equally as solid figures with total sales growing by 13% to $911.7m (www.clinica.co.uk, 29 April 2010).